A citation-based method for searching scientific literature

Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
Times Cited: 508



Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Times Cited: 3053




List of shared articles



Times cited

Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
Hongyan Liu, Vikas S Sridhar, Jacinthe Boulet, Atit Dharia, Abid Khan, Patrick R Lawler, David Z I Cherney. Metabolism 2022
0

Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal. Adv Exp Med Biol 2021
5



Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes.
Nick S R Lan, Bu B Yeap, P Gerry Fegan, Gillian Green, James M Rankin, Girish Dwivedi. Int J Cardiovasc Imaging 2021
2

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Jaime Blais, Qiang Li, Meg J Jardine,[...]. Am J Kidney Dis 2021
7

Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.
Adriana Marton, Tatsuroh Kaneko, Jean-Paul Kovalik, Atsutaka Yasui, Akira Nishiyama, Kento Kitada, Jens Titze. Nat Rev Nephrol 2021
17

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
Emily Brown, John P H Wilding, Uazman Alam, Thomas M Barber, Janaka Karalliedde, Daniel J Cuthbertson. Ann Med 2021
2

Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.
Manfred Hecking, Adnan Sharif, Kathrin Eller, Trond Jenssen. Transpl Int 2021
6

Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors.
Mouhamed Nashawi, Omar Sheikh, Ayman Battisha, Abdullah Ghali, Robert Chilton. Heart Fail Rev 2021
1

Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.
Eirini Papadopoulou, Charalampos Loutradis, Glykeria Tzatzagou, Kalliopi Kotsa, Ioanna Zografou, Ioanna Minopoulou, Marietta P Theodorakopoulou, Apostolos Tsapas, Asterios Karagiannis, Pantelis Sarafidis. J Hypertens 2021
8

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
15

Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Husam M Salah, Subhi J Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L Mehta, J Paul Mounsey, Stephen J Greene, Darren K McGuire, Renato D Lopes,[...]. Am Heart J 2021
17

The role of sodium glucose co-transporter inhibitors in heart failure prevention.
Vishnu Garla, Angela Subauste, Javed Butler, Lillian F Lien. J Diabetes Complications 2021
0


Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model.
Ryo Nishinarita, Shinichi Niwano, Hiroe Niwano, Hironori Nakamura, Daiki Saito, Tetsuro Sato, Gen Matsuura, Yuki Arakawa, Shuhei Kobayashi, Yuki Shirakawa,[...]. J Am Heart Assoc 2021
5

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
Filipe Ferrari, Vítor M Martins, Rafael S Scheffel, Anderson D da Silveira, Marcelo Trotte Motta, Emilio H Moriguchi, Raul D Santos, Ricardo Stein. Ann Pharmacother 2021
1

Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis.
Kai Jiang, Yue Xu, Dandan Wang, Feng Chen, Zizhuo Tu, Jie Qian, Sheng Xu, Yixiang Xu, John Hwa, Jian Li,[...]. Protein Cell 2021
6

Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Paola Caruso, Katherine Esposito. Cardiovasc Diabetol 2021
9

Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis.
Alex Ali Sayour, Csilla Celeng, Attila Oláh, Mihály Ruppert, Béla Merkely, Tamás Radovits. Diabetologia 2021
4

SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
Maja Nikolic, Vladimir Zivkovic, Jovana Joksimovic Jovic, Jasmina Sretenovic, Goran Davidovic, Stefan Simovic, Danijela Djokovic, Nemanja Muric, Sergey Bolevich, Vladimir Jakovljevic. Heart Fail Rev 2021
6

The Effects of SGLT2 Inhibitors on Lipid Metabolism.
Zsolt Szekeres, Kalman Toth, Eszter Szabados. Metabolites 2021
3

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.
Ralph A DeFronzo, W Brian Reeves, Alaa S Awad. Nat Rev Nephrol 2021
21

Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes.
Evdoxia Bletsa, Sebastien Filippas-Dekouan, Christina Kostara, Panagiotis Dafopoulos, Aikaterini Dimou, Eleni Pappa, Styliani Chasapi, Georgios Spyroulias, Anastasios Koutsovasilis, Eleni Bairaktari,[...]. J Clin Endocrinol Metab 2021
1

Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study.
Jonas Oldgren, Sanna Laurila, Axel Åkerblom, Aino Latva-Rasku, Eleni Rebelos, Henrik Isackson, Maria Saarenhovi, Olof Eriksson, Kerstin Heurling, Edvin Johansson,[...]. Diabetes Obes Metab 2021
2

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.
Qingchun Zeng, Qing Zhou, Weitao Liu, Yutong Wang, Xingbo Xu, Dingli Xu. Front Cardiovasc Med 2021
3

Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
B Gaborit, P Ancel, A E Abdullah, F Maurice, I Abdesselam, A Calen, A Soghomonian, M Houssays, I Varlet, M Eisinger,[...]. Cardiovasc Diabetol 2021
3

Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction.
Soo Yong Lee, Tae Wook Lee, Gyu Tae Park, Jae Ho Kim, Hyun Chae Lee, Jung Hwa Han, Aeseon Yoon, Dahye Yoon, Shukmann Kim, Soon Myung Jung,[...]. Korean Circ J 2021
1

Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.
Edimar Alcides Bocchi, Andréa Biolo, Lidia Zytynski Moura, José Albuquerque Figueiredo Neto, Carlos Eduardo Lucena Montenegro, Denilson Campos de Albuquerque. Arq Bras Cardiol 2021
0

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
9

Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class.
Hideaki Kaneto, Atsushi Obata, Tomohiko Kimura, Masashi Shimoda, Tomoe Kinoshita, Taka-Aki Matsuoka, Kohei Kaku. Int J Mol Sci 2021
1




Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén. Diabetes Res Clin Pract 2021
1


Cardiorenal Protection in Diabetic Kidney Disease.
Jason F Lee, Ecaterina Berzan, Vikas S Sridhar, Ayodele Odutayo, David Z I Cherney. Endocrinol Metab (Seoul) 2021
2

Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art Review.
Henri Honka, Carolina Solis-Herrera, Curtis Triplitt, Luke Norton, Javed Butler, Ralph A DeFronzo. J Am Coll Cardiol 2021
0

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors.
Hidekatsu Yanai, Mariko Hakoshima, Hiroki Adachi, Hisayuki Katsuyama. Int J Mol Sci 2021
2

Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats.
Jacob Marthinsen Seefeldt, Thomas Ravn Lassen, Marie Vognstoft Hjortbak, Nichlas Riise Jespersen, Frederikke Kvist, Jakob Hansen, Hans Erik Bøtker. Sci Rep 2021
0

Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
Moritz J Hundertmark, Olorunsola F Agbaje, Ruth Coleman, Jyothis T George, Rolf Grempler, Rury R Holman, Hanan Lamlum, Jisoo Lee, Joanne E Milton, Heiko G Niessen,[...]. ESC Heart Fail 2021
2

SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives.
Vishnu Vardhan Garla, Javed Butler, Lillian F Lien. Curr Cardiol Rep 2021
0

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Hang-Long Li, Gregory Y H Lip, Qi Feng, Yue Fei, Yi-Kei Tse, Mei-Zhen Wu, Qing-Wen Ren, Hung-Fat Tse, Bernard-M Y Cheung, Kai-Hang Yiu. Cardiovasc Diabetol 2021
8

Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction.
Ammar G Chaudhary, Fadi M Alreefi, Mohammad A Aziz. CJC Open 2021
0

Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists.
Francesco Prattichizzo, Paola de Candia, Antonio Ceriello. Metabolism 2021
5

Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial.
Gian Pio Sorice, Francesca Cinti, Lucia Leccisotti, Domenico D'Amario, Margherita Lorusso, Maria Angela Guzzardi, Teresa Mezza, Camilla Cocchi, Umberto Capece, Pietro Manuel Ferraro,[...]. Diabetes Ther 2021
0

Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease.
Mohanad Almaimani, Vikas S Sridhar, David Z I Cherney. Curr Opin Nephrol Hypertens 2021
0

Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?
Michele Correale, Renata Petroni, Stefano Coiro, Elena-Laura Antohi, Francesco Monitillo, Marta Leone, Marco Triggiani, Shiro Ishihara, Hans-Dirk Dungen, Chaudhry M S Sarwar,[...]. Heart Fail Rev 2021
1

Towards precision medicine in heart failure.
Chad S Weldy, Euan A Ashley. Nat Rev Cardiol 2021
0

An evaluation of canagliflozin for the treatment of type 2 diabetes: an update.
Taichi Minami, Akiko Kameda, Yasuo Terauchi. Expert Opin Pharmacother 2021
0